申请人:Actelion Pharmaceuticals Ltd.
公开号:EP2256120A1
公开(公告)日:2010-12-01
The invention relates to novel chimeric antibiotics of formula I
wherein
R1 is heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl;
R2 is H, OH, OSO3H, OPO3H2, OCH2OPO3H2, OCOCH2CH2COOH, OCOR6;
R3 is H or halogen;
R4 is (C1-C3)alkyl, (C1-C3)haloalkyl or cycloalkyl;
R6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine.
These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).
本发明涉及式 I 的新型嵌合抗生素
其中
R1 是杂芳基甲基、杂芳氧基甲基或杂芳基氨基甲基;
R2 是 H、OH、OSO3H、OPO3H2、OCH2OPO3H2、OCOCH2CH2COOH、OCOR6;
R3 是 H 或卤素
R4 是 (C1-C3)烷基、(C1-C3)卤代烷基或环烷基;
R6 是天然氨基酸或二甲氨基甘氨酸的残基。
这些嵌合化合物可用于制造治疗感染(如细菌感染)的药物。